Patents Examined by Patrick J. Nolan
-
Patent number: 7776523Abstract: Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.Type: GrantFiled: December 7, 2001Date of Patent: August 17, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Pablo D. Garcia, Stephen F. Hardy, Jaime Escobedo, Lewis T. Williams
-
Patent number: 7776340Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (eg Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).Type: GrantFiled: July 1, 2003Date of Patent: August 17, 2010Assignee: The Royal Veterinary CollegeInventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
-
Patent number: 7758867Abstract: The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated influenza virus strain and the live vaccine of the present invention are useful for prevention of seasonal influenza episodes and sudden outbreak of influenza pandemics of predicted or unknown identity, since they have safety, efficacy, high production yield, immediate protection against variety of influenza subtypes and prolonged protection against specific influenza subtype.Type: GrantFiled: June 18, 2007Date of Patent: July 20, 2010Assignee: Biotrion Co., Ltd.Inventors: Baik Lin Seong, Kwang Hee Lee, Sang Uk Seo
-
Patent number: 7741453Abstract: The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.Type: GrantFiled: May 31, 2002Date of Patent: June 22, 2010Assignee: Conjuchem Biotechnologies, Inc.Inventors: John W. Erickson, Dominique P. Bridon, Martin Robitaille, Grant A. Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra DeMeyer
-
Patent number: 7740855Abstract: A method for the preparation of a T cell vaccine for the treatment of immunodeficient HIV-infected patients is described herein, based on the enrichment of autologous CD4-reactive CD8 T cells. Also described is a protocol for the implementation of T cell vaccination in immunodeficient HIV-infected, as well as a method of treatment, based on the T cell vaccine developed herein. Finally, kits for preparing the T cell vaccine as well as for implementing the protocol are also provided.Type: GrantFiled: November 30, 2005Date of Patent: June 22, 2010Assignees: Yeda Research & Development Co. Ltd, Hadasit Medical Research Services and Dev. LtdInventors: Rivka Abulafia-Lapid, Henri Atlan, Irun R. Cohen
-
Patent number: 7736642Abstract: The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions.Type: GrantFiled: February 2, 2007Date of Patent: June 15, 2010Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King, Yingnian Lu, Victoria Kelley Hodson
-
Patent number: 7189812Abstract: Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater genomic, cDNA and protein sequences are provided, as are fragments and variants thereof. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for using Mater molecules in diagnoses, prognosis, and treatment of infertility and reduced fertility, and kits related to such methods. Also provided are methods for using MATER as a contraceptive agent. The disclosure also describes compounds involved in such methods, and the identification of such compounds.Type: GrantFiled: October 1, 2003Date of Patent: March 13, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Lawrence M. Nelson, Zhi-Bin Tong
-
Patent number: 7157500Abstract: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body.Type: GrantFiled: August 13, 2002Date of Patent: January 2, 2007Assignee: Brigham and Women's HospitalInventors: Jonathan Stamler, Joseph Loscalzo, Daniel Simon, David Singel
-
Patent number: 7128921Abstract: The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.Type: GrantFiled: September 14, 2000Date of Patent: October 31, 2006Assignee: Heska CorporationInventors: Catherine A. McCall, Shirley Wu Hunter, Eric R. Weber
-
Patent number: 7122336Abstract: This invention relates to the field of therapy and diagnostic methods for ulcerative colitis. Specifically, the method comprises administering a compound or recombinant protein that inhibits interaction between CEP and human tropomyosin. Also included in the invention are methods to screen for drugs useful in treating ulcerative colitis and diagnostic methods for detecting diseases associated with an autoantigen response to hTM in affected tissue.Type: GrantFiled: February 5, 2003Date of Patent: October 17, 2006Assignee: University of Medicine & Dentistry of New JerseyInventor: Kiron M. Das
-
Patent number: 7112325Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme, antibodies to such enzyme, and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.Type: GrantFiled: July 1, 2003Date of Patent: September 26, 2006Assignee: Genetics Institute, LLCInventors: Simon Jones, Jin Tang
-
Patent number: 7112438Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.Type: GrantFiled: October 15, 2002Date of Patent: September 26, 2006Assignee: Dyax Corp.Inventors: Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
-
Patent number: 7108858Abstract: The present invention is drawn to an immunogen derived from a protein allergen, which is a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen which contains an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen; b) a polymeric form of the fragment, in which the fragment constitutes the monomeric units; or c) a non-anaphylactic recombinant polymeric form of the protein allergen having 2–10 monomeric units, in which the protein allergen constitutes the monomeric units. The present invention is further drawn to the use of the immunogen for in vitro diagnoses of type I allergy and hyposensitization.Type: GrantFiled: July 3, 2001Date of Patent: September 19, 2006Assignee: Pharmacia Diagnostics ABInventors: Rudolf Valenta, Susanne Vrtala, Luca Vangelista, Hans-Georg Eichler, Wolfgang R. Sperr, Peter Valent, Christof Ebner, Dietrich Kraft, Hans Grönlund
-
Patent number: 7109306Abstract: The present invention relates to a novel protein, the Human Oncogene Induced Secreted Protein I (“HOIPS I”) protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Antibodies to human HOIPS I are also provided, as are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.Type: GrantFiled: August 3, 2004Date of Patent: September 19, 2006Assignee: Human Genome Sciences, Inc.Inventors: Henrik S. Olsen, Steven M. Ruben
-
Patent number: 7101962Abstract: The present invention relates to modulators of P2Y10. Various modulators are disclosed, including an antibody that binds specifically to P2Y10. The present invention also relates to methods of activating resting T lymphocytes and inhibiting the proliferation of activated T lymphocytes. Methods of upregulating trascription of P2Y10 mRNA in a resting T lymphocyte, methods of inducing expression of P2Y10 on the surface of a resting T lymphocyte and methods of activating a T lymphocyte are disclosed. Also disclosed are pharmaceuticals and methods of treating an immune disease.Type: GrantFiled: May 13, 2004Date of Patent: September 5, 2006Assignee: Bristol-Myers Squibb CompanyInventors: James R. Burke, Violetta Iotzova
-
Patent number: 7098316Abstract: The present invention relates to novel human proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells and recombinant methods for producing the proteins of the invention. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.Type: GrantFiled: December 10, 2002Date of Patent: August 29, 2006Assignees: Human Genome Sciences, Inc., Auckland Uniservices, LimitedInventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Jeffrey Y. Su, Geoffrey Krissansen, Ping Feng
-
Patent number: 7094890Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of cartilage degenerative conditions, including forms of arthritis. In particular, the invention relates to a protein, termed “adlican,” that is differentially transcribed and expressed in human subjects suffering from arthritis, such as osteoarthritis (OA) and rheumatoid arthritis (RA) compared with non-arthritis sufferers, antibodies which recognize this protein, and methods for diagnosing arthritis.Type: GrantFiled: March 10, 2000Date of Patent: August 22, 2006Assignee: Novartis AGInventors: Robert Mitchell Crowl, Daniel C. Luk
-
Patent number: 7094561Abstract: The present invention relates to methods of monitoring the menstrual cycle and/or the first half of pregnancy in a female by assessing the adhesion of lymphocytes from the female to uterine or lymphoid histological tissues from a pregnant animal or an animal that has been treated with gestational hormones. The method can be used to determine the ability of the lymphocyte donor's immune system to recognize and respond to an environment suitable for sustaining a pregnancy.Type: GrantFiled: October 25, 2002Date of Patent: August 22, 2006Assignees: University of Guelph, Health Research, Inc., Roswell Park DivisionInventors: Barbara Anne Croy, Sharon S. Evans
-
Patent number: 7087726Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).Type: GrantFiled: January 9, 2002Date of Patent: August 8, 2006Assignee: Genentech, Inc.Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
-
Patent number: 7084260Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.Type: GrantFiled: October 10, 1996Date of Patent: August 1, 2006Assignee: GenPharm International, Inc.Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild